Form 4: aTyr Pharma Director Timothy Coughlin Acquires 24,000 Stock Options

Director Timothy Coughlin acquired 24,000 stock options in aTyr Pharma, Inc. on May 22, 2024, according to a Form 4 filing with the SEC.

Summary

• On May 22, 2024, Timothy Coughlin, a director of aTyr Pharma, Inc., acquired 24,000 stock options.
• The options have an exercise price of $1.86.
• The options were granted pursuant to the Issuer's non-employee director compensation policy.
• The options vest in full on the earlier of May 22, 2025, or the Issuer's 2025 Annual Meeting of Stockholders, subject to continued service on the Board of Directors.
• The expiration date for the options is May 22, 2034.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option grants to a director, which is a common practice. It doesn't inherently indicate positive or negative sentiment, but rather provides transparency.

Positives

• The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.

Industry Context

This filing is a routine disclosure related to insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The acquisition of stock options by a director could have a minor positive impact on shareholder sentiment.

Key Dates